scholarly journals Nanoparticle Delivered Anti-miR-141-3p for Stroke Therapy

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1011
Author(s):  
Karishma Dhuri ◽  
Rutesh N. Vyas ◽  
Leslie Blumenfeld ◽  
Rajkumar Verma ◽  
Raman Bahal
Keyword(s):  
Ischemic Stroke ◽  
Nucleic Acid ◽  
Double Emulsion ◽  
Artery Occlusion ◽  
Brain Parenchyma ◽  
Confocal Imaging ◽  
In Vivo Studies ◽  
Stroke Therapy ◽  
Systemic Delivery

Ischemic stroke and factors modifying ischemic stroke responses, such as social isolation, contribute to long-term disability worldwide. Several studies demonstrated that the aberrant levels of microRNAs contribute to ischemic stroke injury. In prior studies, we established that miR-141-3p increases after ischemic stroke and post-stroke isolation. Herein, we explored two different anti-miR oligonucleotides; peptide nucleic acid (PNAs) and phosphorothioates (PS) for ischemic stroke therapy. We used US FDA approved biocompatible poly (lactic-co-glycolic acid) (PLGA)-based nanoparticle formulations for delivery. The PNA and PS anti-miRs were encapsulated in PLGA nanoparticles by double emulsion solvent evaporation technique. All the formulated nanoparticles showed uniform morphology, size, distribution, and surface charge density. Nanoparticles also exhibited a controlled nucleic acid release profile for 48 h. Further, we performed in vivo studies in the mouse model of ischemic stroke. Ischemic stroke was induced by transient (60 min) occlusion of middle cerebral artery occlusion followed by a reperfusion for 48 or 72 h. We assessed the blood-brain barrier permeability of PLGA NPs containing fluorophore (TAMRA) anti-miR probe after systemic delivery. Confocal imaging shows uptake of fluorophore tagged anti-miR in the brain parenchyma. Next, we evaluated the therapeutic efficacy after systemic delivery of nanoparticles containing PNA and PS anti-miR-141-3p in mice after stroke. Post-treatment differentially reduced both miR-141-3p levels in brain tissue and infarct injury. We noted PNA-based anti-miR showed superior efficacy compared to PS-based anti-miR. Herein, we successfully established that nanoparticles encapsulating PNA or PS-based anti-miRs-141-3p probes could be used as a potential treatment for ischemic stroke.

Abstract P774: Therapeutic Efficacy of Next Generation Anti-miR-141-3p for Ischemic Stroke

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Karishma Dhuri ◽  
Leslie Blumenfeld ◽  
Raman Bahal ◽  
Rajkumar Verma
Keyword(s):  
Particle Size ◽  
Ischemic Stroke ◽  
Solid Phase ◽  
Double Emulsion ◽  
Artery Occlusion ◽  
Hydrodynamic Diameter ◽  
Stroke Therapy ◽  
Evaporation Technique ◽  
Cerebral Artery Occlusion

Background: Stroke and factors modifying stroke responses, such as social isolation, increases miR-141-3p. Hence, inhibiting miR-141-3p can be a promising stroke therapy. Unfortunately, commercially available miR-141-3p inhibitors cannot be used for therapeutic purpose due to several limitations; use of viral or non-viral transfection reagents for cell penetration, in vivo instability of anti-miRs and toxicity of synthetic anti-miRs. Therefore, we explored phosphorothioates (PS) and peptide nucleic acids (PNAs) based anti-miR-141-3p encapsulated in poly (lactide-co-glycolide) (PLGA)-based nanoparticles (NPs) for potential stroke therapy. Methods: PNAs and PS anti-miR 141-3p were synthesized in house using solid phase synthesis and purchased from a commercial vendor, respectively. The anti-miRs were encapsulated in PLGA NP by double emulsion solvent evaporation technique. For in vivo efficacy 8-10 weeks old C57BL/6 male mice were pair-housed (PH) for at least two weeks. After two weeks, a 60-minute right middle cerebral artery occlusion surgery (MCAO) was performed and mice were kept individually. The mice were then randomly assigned to receive NPs of either anti-miR-141-3p PNA or anti-miR-141-3p phosphorothioate (PS) or scrambled control (Sc) through lateral tail vein 4 hrs. after stroke. To measure NPs of PS were conjugated with fluorophore (TAMRA) to measure BBB permeability. The effect of inhibitor treatment was evaluated at 3 days after stroke. Results: The formulated NPs show uniform morphology with a mean dry particle size <120 nm and an average hydrodynamic diameter of 350 nm. The NPs exhibit an average polydispersity index of 0.1-0.2 indicating homogenous particle size distribution. Single dose of anti-miR 141 and (NPs containing 0.05mg/kg i.v of total either PNA or PS) Both the NPs of PNA and PS significantly reduced (P<0.05 vs. Sc) infarct injury and neurological deficit. Anti-miR of PNA and PS reduce 6 and 5-fold respectively of miR-141-3p in the brain tissue. Conclusion: Our NPs are BBB permeable. PNA based anti-miR-141 are more potent the PS based anti-miR Reduced miR-141-3p levels as well as infarct injury by both PS and PNA based anti-miR 141-3p suggest the efficacy of our novel ant-miR -141-3p for the treatment of ischemic stroke.

scholarly journals Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: A systematic review of preclinical in vivo studies

2021 ◽  
pp. 0271678X2110399
Author(s):  
Laura Skukan ◽  
Matea Brezak ◽  
Rok Ister ◽  
Lars Klimaschewski ◽  
Aleksandar Vojta ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Ischemic Stroke ◽  
Viral Vector ◽  
Infarct Volume ◽  
Meta Analysis ◽  
Artery Occlusion ◽  
In Vivo Studies ◽  
Specific Cell ◽  
Systematic Analysis

Due to the limited therapeutic options after ischemic stroke, gene therapy has emerged as a promising choice, especially with recent advances in viral vector delivery systems. Therefore, we aimed to provide the current state of the art of lentivirus (LV) and adeno-associated virus (AAV) mediated gene interventions in preclinical ischemic stroke models. A systematic analysis including qualitative and quantitative syntheses of studies published until December 2020 was performed. Most of the 87 selected publications used adult male rodents and the preferred stroke model was transient middle cerebral artery occlusion. LV and AAV vectors were equally used for transgene delivery, however loads of AAVs were higher than LVs. Serotypes having broad cell tropism, the use of constitutive promoters, and virus delivery before the stroke induction via stereotaxic injection in the cortex and striatum were preferred in the analyzed studies. The meta-analysis based on infarct volume as the primary outcome confirmed the efficacy of the preclinical interventions. The quality assessment exposed publication bias and setbacks in regard to risks of bias and study relevance. The translational potential could increase by using specific cell targeting, post-stroke interventions, non-invasive systematic delivery, and use of large animals.

Abstract 64: Perlecan LG3 is Neuroprotective When Administered Intra-arterially After Experimental Ischemic Stroke

Stroke ◽  
2016 ◽  
Vol 47 (suppl_1) ◽  
Author(s):  
Kathleen Salmeron ◽  
Michael Maniskas ◽  
Justin Fraser ◽  
Gregory Bix
Keyword(s):  
Ischemic Stroke ◽  
Therapeutic Potential ◽  
Vital Signs ◽  
Artery Occlusion ◽  
Experimental Stroke ◽  
Stroke Therapy ◽  
Treatment Conditions ◽  
Endogenous Protection

Despite recent advances in stroke therapy, stroke remains a leading cause of morbidity and mortality. We have previously demonstrated the therapeutic potential of exploiting the brain’s endogenous protection and repair processes following stroke. Specifically, we reported that the LG3 protein fragment of the heparan sulfate proteoglycan perlecan is neuroprotective and proangiogenic in vitro. We now hypothesize that LG3 could be therapeutic in experimental stroke. However, as previous in vivo LG3 studies suggest that it may not readily target stroke-affected brain upon systemic administration, we administered LG3 in a super selective intra-arterial (IA) model (into the ipsilateral common carotid artery) following transient (1 hour) middle cerebral artery occlusion in 3 month old male mice. Upon reperfusion the mice received LG3 or vehicle controls via IP (5 mg/kg) or IA (0.15 mg/kg) administration. No differences in vital signs were noted between the treatment groups. We observed that all LG3 treated mice, regardless of route of administration, had a smaller infarct compared to controls on post-stroke day 3. Importantly, those mice that received IA LG3 had much smaller strokes and performed significantly better in forced movement and in free movement settings than all other treatment conditions. Our results demonstrate that acute LG3 administration is beneficial after experimental ischemic stroke, IA LG3 is safe and much more effective than IP, and support further investigation of LG3 as a novel acute stroke therapy.

scholarly journals Up-regulation of miR-499a-5p decreases cerebral ischemia/reperfusion injury by targeting PDCD4

2021 ◽  
Author(s):  
Weifeng Shan ◽  
Huifeng Ge ◽  
Bingquan Chen ◽  
Linger Huang ◽  
Shaojun Zhu ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Cerebral Ischemia ◽  
Ischemia Reperfusion Injury ◽  
Cell Model ◽  
Ischemia Reperfusion ◽  
Glucose Deprivation ◽  
Artery Occlusion ◽  
Tunel Staining ◽  
Cerebral Ischemia Reperfusion

Abstract MiR-499a-5p was significantly down-regulated in degenerative tissues and correlated with apoptosis. Nonetheless, the biological function of miR-499a-5p in acute ischemic stroke has been still unclear. In this study, we found the plasma levels of miR-499a-5p were significantly down-regulated in 64 ischemic stroke patients and negatively correlated with the National Institutes of Health Stroke Scale score. Then, we constructed cerebral ischemia/reperfusion (I/R) injury in rats after middle cerebral artery occlusion and subsequent reperfusion and oxygen-glucose deprivation and reoxygenation (OGD/R) treated SH-SY5Y cell model. Transfection with miR-499a-5p mimic was accomplished by intracerebroventricular injection in the in vivo I/R injury model. We further found miR-499a-5p overexpression decreased infarct volumes and cell apoptosis in the in vivo I/R stroke model using TTC and TUNEL staining. PDCD4 was a direct target of miR-499a-5p by luciferase report assay and western blotting. Knockdown of PDCD4 reduced the infarct damage and cortical neuron apoptosis caused by I/R injury. MiR-499a-5p exerted neuroprotective roles mainly through inhibiting PDCD4-mediated apoptosis by CCK-8 assay, LDH release assay and flow cytometry analysis. These findings suggest that miR-499a-5p might represent a novel target that regulates brain injury by inhibiting PDCD4-mediating apoptosis.

Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma

2021 ◽  
pp. 1-11
Author(s):  
Yuzaburo Shimizu ◽  
Joy Gumin ◽  
Feng Gao ◽  
Anwar Hossain ◽  
Elizabeth J. Shpall ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Human Mesenchymal Stem Cells ◽  
Oncolytic Viruses ◽  
In Vivo Studies ◽  
Systemic Delivery ◽  
Previously Treated

OBJECTIVE Delta-24-RGD is an oncolytic adenovirus that is capable of replicating in and killing human glioma cells. Although intratumoral delivery of Delta-24-RGD can be effective, systemic delivery would improve its clinical application. Bone marrow–derived human mesenchymal stem cells (BM-hMSCs) obtained from healthy donors have been investigated as virus carriers. However, it is unclear whether BM-hMSCs can be derived from glioma patients previously treated with marrow-toxic chemotherapy or whether such BM-hMSCs can deliver oncolytic viruses effectively. Herein, the authors undertook a prospective clinical trial to determine the feasibility of obtaining BM-hMSCs from patients with recurrent malignant glioma who were previously exposed to marrow-toxic chemotherapy. METHODS The authors enrolled 5 consecutive patients who had been treated with radiation therapy and chemotherapy. BM aspirates were obtained from the iliac crest and were cultured to obtain BM-hMSCs. RESULTS The patient-derived BM-hMSCs (PD-BM-hMSCs) had a morphology similar to that of healthy donor–derived BM-hMSCs (HD-BM-hMSCs). Flow cytometry revealed that all 5 cell lines expressed canonical MSC surface markers. Importantly, these cultures could be made to differentiate into osteocytes, adipocytes, and chondrocytes. In all cases, the PD-BM-hMSCs homed to intracranial glioma xenografts in mice after intracarotid delivery as effectively as HD-BM-hMSCs. The PD-BM-hMSCs loaded with Delta-24-RGD (PD-BM-MSC-D24) effectively eradicated human gliomas in vitro. In in vivo studies, intravascular administration of PD-BM-MSC-D24 increased the survival of mice harboring U87MG gliomas. CONCLUSIONS The authors conclude that BM-hMSCs can be acquired from patients previously treated with marrow-toxic chemotherapy and that these PD-BM-hMSCs are effective carriers for oncolytic viruses.

Nanoparticle-targeted delivery of nonanticoagulant heparin and doxorubicin in doxorubicin-resistant breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11599-e11599
Author(s):  
D. J. Bharali ◽  
M. Yalcin ◽  
U. Dier ◽  
S. Mousa ◽  
S. Mousa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Delivery ◽  
Double Emulsion ◽  
Chemotherapeutic Agents ◽  
Confocal Imaging ◽  
Breast Cancer Patients ◽  
Cell Viability Assay ◽  
Custom Made

e11599 Background: In comparison to low molecular weight heparin (LMWH), non-anticoagulant heparin (NACH), originally developed in our laboratory, has minimal effects on hemostasis. Encapsulation of chemotherapeutic agents and NACH in biodegradable nanoparticles has tremendous potential in improving survival among the breast cancer patients. Furthermore, custom-made nanoparticles with a targeted moiety on the surface would enable us to increase the efficacy and decrease the adverse effects of doxorubicin. Methods: PLGA-PEG nanoparticles co-encapsulating NACH and doxorubicin were synthesized by double emulsion solvent evaporation method. The in vitro efficacy of these nanoparticles was examined in MCF-7 doxorubicin resistant (MCF-7R) cells using MTT cell viability assay. Confocal microscopy was used to examine the uptake of αvβ3 antibody conjugated nanoparticles in human dermal microvascular endothelial cells (HDMEC), which are known to over express αvβ3 integrins. Results: Size measurement by DLS revealed that these nanoparticles co-encapsulating doxorubicin and heparins to be 200–300 nm in size. Data from the MTT assays in MCF-7R cells showed synergy between NACH and doxorubicin when encapsulated in PLGA-PEG nanoparticles. Confocal imaging in HDMEC cells indicates that these nanoparticles have the potential to be used for site specific delivery to the tumor neovascularization. In vivo data in nude mice xenograft (MCF-7R) are shown in the table below (doses of doxorubicin and NACH injected subcutaneously were 0.625 mg/kg and 2.5 mg/kg body weight, respectively). Significant decrease in tumor weight was observed in the mice xenograft, when treated with αvβ3 conjugated nanoparticles co-encapsulating doxorubcin or to greater extent doxorubicin and NACH compares to its non encapsulated counterparts. Conclusions: These data indicated distinct improvement in the anti-tumor efficacy using αvβ3site directed delivery doxorubicin and NACH encapsulted in PLGA-PEG nanoparticles. [Table: see text] No significant financial relationships to disclose.

scholarly journals Delayed inhibition of tonic inhibition enhances functional recovery following experimental ischemic stroke

2017 ◽  
Vol 39 (6) ◽  
pp. 1005-1014 ◽  
Author(s):  
James E Orfila ◽  
Himmat Grewal ◽  
Robert M Dietz ◽  
Frank Strnad ◽  
Takeru Shimizu ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Functional Recovery ◽  
Ex Vivo ◽  
Long Term Potentiation ◽  
Artery Occlusion ◽  
Memory Impairments ◽  
Time Points ◽  
Term Potentiation ◽  
Cerebral Artery Occlusion

The current study focuses on the ability to improve cognitive function after stroke with interventions administered at delayed/chronic time points. In light of recent studies demonstrating delayed GABA antagonists improve motor function, we utilized electrophysiology, biochemistry and neurobehavioral methods to investigate the role of α5 GABAA receptors on hippocampal plasticity and functional recovery following ischemic stroke. Male C57Bl/6 mice were exposed to 45 min transient middle cerebral artery occlusion and analysis of synaptic and functional deficits performed 7 or 30 days after recovery. Our findings indicate that hippocampal long-term potentiation (LTP) is impaired 7 days after stroke and remain impaired for at least 30 days. We demonstrate that ex vivo administration of L655,708 reversed ischemia-induced plasticity deficits and importantly, in vivo administration at delayed time-points reversed stroke-induced memory deficits. Western blot analysis of hippocampal tissue reveals proteins responsible for GABA synthesis are upregulated (GAD65/67 and MAOB), increasing GABA in hippocampal interneurons 30 days after stroke. Thus, our data indicate that both synaptic plasticity and memory impairments observed after stroke are caused by excessive tonic GABA activity, making inhibition of specific GABA activity at delayed timepoints a potential therapeutic approach to improve functional recovery and reverse cognitive impairments after stroke.

scholarly journals Polyethyleneimine-Based Lipopolyplexes as Carriers in Anticancer Gene Therapies

Materials ◽  
2021 ◽  
Vol 15 (1) ◽  
pp. 179
Author(s):  
Julia Jerzykiewicz ◽  
Aleksander Czogalla
Keyword(s):  
Nucleic Acid ◽  
Cancer Treatment ◽  
Future Development ◽  
Viral Vectors ◽  
Lipid Vesicles ◽  
Therapeutic Strategies ◽  
In Vivo Studies ◽  
Great Promise ◽  
Gene Therapies

Recent years have witnessed rapidly growing interest in application of gene therapies for cancer treatment. However, this strategy requires nucleic acid carriers that are both effective and safe. In this context, non-viral vectors have advantages over their viral counterparts. In particular, lipopolyplexes—nanocomplexes consisting of nucleic acids condensed with polyvalent molecules and enclosed in lipid vesicles—currently offer great promise. In this article, we briefly review the major aspects of developing such non-viral vectors based on polyethyleneimine and outline their properties in light of anticancer therapeutic strategies. Finally, examples of current in vivo studies involving such lipopolyplexes and possibilities for their future development are presented.

scholarly journals Supplemental N-3 Polyunsaturated Fatty Acids Limit A1-Specific Astrocyte Polarization via Attenuating Mitochondrial Dysfunction in Ischemic Stroke in Mice

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Jun Cao ◽  
Lijun Dong ◽  
Jialiang Luo ◽  
Fanning Zeng ◽  
Zexuan Hong ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Ischemic Stroke ◽  
Polyunsaturated Fatty Acids ◽  
Mitochondrial Dysfunction ◽  
Artery Occlusion ◽  
Mice Model ◽  
Neuron Death ◽  
The Impact

Ischemic stroke is one of the leading causes of death and disability for adults, which lacks effective treatments. Dietary intake of n-3 polyunsaturated fatty acids (n-3 PUFAs) exerts beneficial effects on ischemic stroke by attenuating neuron death and inflammation induced by microglial activation. However, the impact and mechanism of n-3 PUFAs on astrocyte function during stroke have not yet been well investigated. Our current study found that dietary n-3 PUFAs decreased the infarction volume and improved the neurofunction in the mice model of transient middle cerebral artery occlusion (tMCAO). Notably, n-3 PUFAs reduced the stroke-induced A1 astrocyte polarization both in vivo and in vitro. We have demonstrated that exogenous n-3 PUFAs attenuated mitochondrial oxidative stress and increased the mitophagy of astrocytes in the condition of hypoxia. Furthermore, we provided evidence that treatment with the mitochondrial-derived antioxidant, mito-TEMPO, abrogated the n-3 PUFA-mediated regulation of A1 astrocyte polarization upon hypoxia treatment. Together, this study highlighted that n-3 PUFAs prevent mitochondrial dysfunction, thereby limiting A1-specific astrocyte polarization and subsequently improving the neurological outcomes of mice with ischemic stroke.

Sign in / Sign up

Export Citation Format

Share Document